Fengshen Kuo
- Oncology top 2%
- Molecular Biology top 10%
- Immunology top 5%
- Pulmonary and Respiratory Medicine top 5%
- Cancer Research top 5%
- Co-authors
- Timothy A. ChanNadeem RiazLuc G.T. MorrisDiego ChowellA. Ari HakimiVladimir MakarovNaiyer A. RizviRuhong Zhou
- Topics
- Renal cell carcinoma treatment (16 papers)Cancer Immunotherapy and Biomarkers (14 papers)Ferroptosis and cancer prognosis (9 papers)
- Cited by
- OncologyImmunologyCancer Research
- Journals
- NatureScienceNature Medicine
- Partner nations
- United StatesGermanyIsrael
In The Last Decade
Fengshen Kuo
52 papers receiving 2.4k citations
Hit Papers
Peers
Comparison fields: 5 of 103
- Oncology 1.3k
- Molecular Biology 819
- Immunology 789
- Pulmonary and Respiratory Medicine 770
- Cancer Research 519
Countries citing papers authored by Fengshen Kuo
This map shows the geographic impact of Fengshen Kuo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fengshen Kuo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fengshen Kuo more than expected).
Fields of papers citing papers by Fengshen Kuo
This network shows the impact of papers produced by Fengshen Kuo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fengshen Kuo. The network helps show where Fengshen Kuo may publish in the future.
Co-authorship network of co-authors of Fengshen Kuo
This figure shows the co-authorship network connecting the top 25 collaborators of Fengshen Kuo. A scholar is included among the top collaborators of Fengshen Kuo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fengshen Kuo. Fengshen Kuo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 2 | |
| 3 | 3 | |
| 4 | 1 | |
| 5 | 27 | |
| 6 | 5 | |
| 7 | 14 | |
| 8 | 20 | |
| 9 | 11 | |
| 10 | 55 | |
| 11 | 4 | |
| 12 | 9 | |
| 13 | 9 | |
| 14 | 79 | |
| 15 | 12 | |
| 16 | 44 | |
| 17 | 156 | |
| 18 | 127 | |
| 19 | 107 | |
| 20 | Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapybreakdown → | 738 |
About Fengshen Kuo
Fengshen Kuo is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine and Oncology, having authored 56 papers that have together received 2.4k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (16 papers), Cancer Immunotherapy and Biomarkers (14 papers) and Ferroptosis and cancer prognosis (9 papers). The work is most often cited by research in Oncology (1.3k citations), Immunology (789 citations) and Cancer Research (519 citations). Fengshen Kuo has collaborated with scholars based in United States, Germany and Israel. Frequent co-authors include Timothy A. Chan, Nadeem Riaz, Luc G.T. Morris, Diego Chowell, A. Ari Hakimi, Vladimir Makarov, Naiyer A. Rizvi, Ruhong Zhou, Sviatoslav M. Kendall and Benjamin D. Greenbaum. Their work appears in journals such as Nature, Science and Nature Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.